Copy
The Longevity Reporter: The Weekly Newsletter About Aging (subscribe to the newsletter)
View this email in your browser
18th March 2017
Connect With Us And Join The Discussion
Facebook
Twitter
Website
Email
This Week's Top Health And Longevity News 
Enzyme Found That Can Prevent Senescence: An enzyme called SETD8 appears to play a critical role in cellular senescence onset. Source 
Repairing Nerve Damage in Multiple Sclerosis: Scientists have discovered a protein secreted by immune cells which regenerates lost myelin in damaged nerve fibres. Source 
CRISPR Could Protect Against Vision Loss In Retinal Disease: Silencing a gene Nrl can prevent the loss of photoreceptor cells in a model of degenerative retinal disease . Source 
Intensive Treatment May Reverse Type 2 Diabetes In Around 40% Of Patients: A intense treatment regime involving oral medications, insulin, and lifestyle changes proved able to induce a 3 month remission in 40% of type 2 diabetics. Source 
Genetic variant accelerates normal brain aging in older people by up to 12 years: Columbia University Medical Center (CUMC) researchers have discovered a common genetic variant that greatly impacts normal brain aging, starting at around age 65, and may modify the risk for neurodegenerative diseases. Source 
Cancer Drug That Might Slow Parkinson's, Alzheimer's Headed For Bigger Tests: Scientists are hoping that a single drug can treat two devastating brain diseases: Parkinson's and Alzheimer's. The drug is nilotinib, which is approved to treat a form of leukemia. Source 
Want More Longevity News -- Follow Us On Twitter, And Like Us On Facebook To Keep Updated On The Latest News About Longevity and Aging
Facebook
Twitter
Website
Spread The Word About Longevity...Share This Newsletter
Share
Tweet
Share
Forward
+1
This newsletter was created and edited by Robert Powles and Avi Roy.
 

Copyright © 2017 The Longevity Reporter, All rights reserved.



subscribe to this list

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp